Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

27 January 2021

Access to Medicine and COVID-19

Writing for Pharma Times, Jayasree K. Iyer reports on the findings of the 2021 Access to Medicine Index and describes how the COVID-19 has put the pharmaceutical industry and health systems to the test.

Jayasree refers to the positive, albeit limited, progress of the pharmaceutical companies to systematically pair candidate products with access plans, offering a few examples of best practice. Yet, she notes that a large portion of the products already available on the market remain unsupported by access plans.

She then compares the industry's response to the COVID-19 pandemic with the response to other infectious diseases identified as pandemic risks and concludes that the lessons learnt from this can guide the companies to become a catalyst for change in future.

Read the full article here.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved